Setback to Roche hopes for Tecentriq as fails key cancer trial – Reuters
Reuters |
Setback to Roche hopes for Tecentriq as fails key cancer trial
Reuters Tecentriq is already approved for some lung cancer patients and bladder cancer, but Roche, the world's biggest oncology drugs maker, is running multiple trials of the immunotherapy as it seeks to expand it range of uses. Trials against some lung … Roche-Exelixis Study Fails as Mixed Year Continues For Cancer Drug Combos Another IO knockback as Tecentriq combo fails phase III trial |
